Arg-Leu-Tyr-Glu Suppresses Retinal Endothelial Permeability and Choroidal Neovascularization by Inhibiting the VEGF Receptor 2 Signaling Pathway |
Park, Wonjin
(Department of Molecular and Cellular Biochemistry, School of Medicine, Kangwon National University)
Baek, Yi-Yong (Department of Molecular and Cellular Biochemistry, School of Medicine, Kangwon National University) Kim, Joohwan (Department of Molecular and Cellular Biochemistry, School of Medicine, Kangwon National University) Jo, Dong Hyun (Fight Against Angiogenesis-Related Blindness (FARB) Laboratory, Clinical Research Institute, Seoul National University Hospital) Choi, Seunghwan (Department of Molecular and Cellular Biochemistry, School of Medicine, Kangwon National University) Kim, Jin Hyoung (Fight Against Angiogenesis-Related Blindness (FARB) Laboratory, Clinical Research Institute, Seoul National University Hospital) Kim, Taesam (Department of Molecular and Cellular Biochemistry, School of Medicine, Kangwon National University) Kim, Suji (Department of Molecular and Cellular Biochemistry, School of Medicine, Kangwon National University) Park, Minsik (Department of Molecular and Cellular Biochemistry, School of Medicine, Kangwon National University) Kim, Ji Yoon (Department of Anesthesiology and Pain Medicine, Hanyang University Hospital) Won, Moo-Ho (Department of Neurobiology, School of Medicine, Kangwon National University) Ha, Kwon-Soo (Department of Molecular and Cellular Biochemistry, School of Medicine, Kangwon National University) Kim, Jeong Hun (Fight Against Angiogenesis-Related Blindness (FARB) Laboratory, Clinical Research Institute, Seoul National University Hospital) Kwon, Young-Guen (Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University) Kim, Young-Myeong (Department of Molecular and Cellular Biochemistry, School of Medicine, Kangwon National University) |
1 | Cao, L., Weetall, M., Bombard, J., Qi, H., Arasu, T., Lennox, W., Hedrick, J., Sheedy, J., Risher, N., Brooks, P. C., Trifillis, P., Trotta, C., Moon, Y. C., Babiak, J., Almstead, N. G., Colacino, J. M., Davis, T. W. and Peltz, S. W. (2016) Discovery of novel small molecule inhibitors of VEGF expression in tumor cells using a cell-based high throughput screening platform. PLoS ONE 11, e0168366. DOI |
2 | Carmeliet, P. (2005) VEGF as a key mediator of angiogenesis in cancer. Oncology 69 Suppl 3, 4-10. DOI |
3 | CATT Research Group, Martin, D. F., Maguire, M. G., Ying, G. S., Grunwald, J. E., Fine, S. L. and Jaffe, G. J. (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364, 1897-1908. DOI |
4 | Cunha-Vaz, J., Bernardes, R. and Lobo, C. (2011) Blood-retinal barrier. Eur. J. Ophthalmol. 21 Suppl 6, S3-S9. DOI |
5 | Di Lorenzo, A., Lin, M. I., Murata, T., Landskroner-Eiger, S., Schleicher, M., Kothiya, M., Iwakiri, Y., Yu, J., Huang, P. L. and Sessa, W. C. (2013) eNOS-derived nitric oxide regulates endothelial barrier function through VE-cadherin and Rho GTPases. J. Cell Sci. 126, 5541-5552. DOI |
6 | Yan, Z., Shi, H., Zhu, R., Li, L., Qin, B., Kang, L., Chen H. and Guan H. (2018) Inhibition of YAP ameliorates choroidal neovascularization via inhibiting endothelial cell proliferation. Mol. Vis. 24, 83-93. |
7 | Ferrara, N. (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 4, 581-611. DOI |
8 | Ferrara, N. and Adamis, A. P. (2016) Ten years of anti-vascular endothelial growth factor therapy. Nat. Rev. Drug. Discov. 6, 385-403. DOI |
9 | Ferrara, N., Gerber, H. P. and LeCounter, J. (2003) The biology of VEGF and its receptors. Nat. Med. 6, 669-676. |
10 | Ferrara, N., Mass, R. D., Campa, C. and Kim, R. (2007) Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu. Rev. Med. 58, 491-504. DOI |
11 | Ferrara, N. (2010) Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat. Med. 16, 1107-1111. DOI |
12 | Grisanti, S. and Tatar, O. (2008) The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog. Retin. Eye. Res. 24, 372-390. DOI |
13 | Hernandez-Zimbron, L. F., Zamora-Alvarado, R., Ochoa-De, la. Paz. L., Velez-Montoya, R., Zenteno, E., Gulias-Canizo, R., Quiroz-Mercado, H. and Gonzalez-Salinas, R. (2018) Age-related macular degeneration: New paradigms for treatment and management of AMD. Oxid. Med. Cell. Longev. 1, 8374647. |
14 | Hofer, E. and Schweighofer, B. (2007) Signal transduction induced in endothelial cells by growth factor receptors involved in angiogenesis. Thromb. Haemost. 97, 355-363. DOI |
15 | Holz, F. G., Schmitz-Valckenberg, S. and Fleckenstein, M. (2014) Recent developments in the treatment of age-related macular degeneration. J. Clin. Invest. 124, 1430-1438. DOI |
16 | Jo, D. H., Kim, J. H., Yang, W., Kim, H., Chang, S., Kim, D., Chang, M., Lee, K., Chung, J. and Kim, J. H. (2017) Anti-complement component 5 antibody targeting MG4 domain inhibits choroidal neovascularization. Oncotarget 8, 45506-45516. DOI |
17 | Kim, J., Kim, T. E., Kim, J. A., Yun, J. H., Sohn, S., Shim, S. R., Lee, S. H. and Kim, S. J. (2014) Intravitreal tanibirumab, a fully human monoclonal antibody against vascular endothelial growth factor receptor 2, partially suppresses and regresses laser-induced choroidal neovascularization in a rat model. J. Ocul. Pharmacol. Ther. 10, 847-853. |
18 | Karar, J. and Maity, A. (2011) PI3K/Akt/mTOR pathway in angiogenesis. Front. Mol. NeuroSci. 4, 51. DOI |
19 | Kashani, A. H., Lebkowski, J. S., Rahhal, F. M., Avery, R. L., Salehi-Had, H., Dang, W., Lin, C. M., Mitra, D., Zhu, D., Thomas, B. B., Hikita, S. T., Pennington, B. O., Johnson, L. V., Clegg, D. O., Hinton, D. R. and Humayun, M. S. (2018) A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration. Sci. Transl. Med. 10, 435. |
20 | Kauppinen, A., Jussi, J., Paterno., Blasiak, J., Salminen, A. and Kaarniranta, K. (2016) Inflammation and its role in age-related macular degeneration. Cell. Mol. Life. Sci. 73, 1765-1786. DOI |
21 | Klein, R., Klein, B. E., Knudtson, M. D., Wong, T. Y., Cotch, M. F., Liu, K., Burke, G., Saad, M. F. and Jacobs, D. R., Jr. (2006) Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. Ophthlamology 113, 373-380. DOI |
22 | Klein, R., Klein, B. E., Knudtson, M. D., Meuer, S. M., Swift, M. and Gangnon, R. E. (2007) Fifteen-year cumulative incidence of age-related macular degeneration: the beaver dam eye study. Ophthalmology 114, 253-262. DOI |
23 | Lambert, V., Lecomte, J., Hansen, S., Blacher, S., Conzalez, M. L., Struman, I., Sounni, N. E., Rozet, E., de, Tullio, P., Foidart, J. M., Rakic, J. M. and Noel, A. (2013) Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice. Nat. Protoc. 11, 2197-2211. |
24 | Miller, J. W., Adamis, A. P., Shima, D. T., D'Amore, P. A., Moulton, R. S., O'Reilly, M. S., Folkman, J., Dvorak, H. F., Brown, L. F., Berse, B., Yeo, T.-K. and Yeo, K.-T. (1994) Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am. J. Pathol. 145, 574-584. |
25 | Langenkamp, E. and Molema, G. (2009) Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer. Cell. Tissue. Res. 335, 205-222. DOI |
26 | Liu, M., Kluger, M. S., D'Alessio, A., Garcia-Cardena, G. and Pober, J. S. (2008) Regulation of arterial-venous differences in tumor necrosis factor responsiveness of endothelial cells by anatomic context. Am. J. Pathol. 72, 1088-1099. |
27 | Miler, J. W., Le, Couter, J., Strauss, E. C. and Ferrara, N. (2013) Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology 120, 106-114. DOI |
28 | Mitchell, P., Liew, G., Gopinath, B. and Wong, T. Y. (2018) Age-related macular degeneration. Lancet 392, 1147-1159. DOI |
29 |
Park, M., Choi, S., Kim, S., Kim, J., Lee, D. K., Park, W., Kim, T., Jung, J., Hwang, J. Y., Won, M. H., Ryoo, S., Kang, S. G., Ha, K. S., Kwon, Y. G. and Kim, Y. M. (2019) NF- |
30 | Neves, Cardoso, P., Pinheiro, A. F., Meira, J., Pedrosa, A. C., Falcao, M. S., Pinheiro-Costa,J., Falcao-Reis, F. and Carneiro, A. M. (2017) Switch to aflibercept in the treatment of neovascular AMD: long-term results. J. Ophthalmol. 2017, 6835782. |
31 | Park, U. C., Shin, J. Y., McCarthy, L. C., Kim, S. J., Park, J. H., Chung, H. and Yu, H. G. (2014) Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients. Mol. Vis. 20, 1680-1694. |
32 | Angkawinitwong, U., Awwad, S., Khaw, P. T., Brocchini, S. and Williams, G. R. (2017) Electrospun formulations of bevacizumab for sustained release in the eye. Acta Biomater. 64,126-136. DOI |
33 | Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., Nguyen, H. V., Aiello, L. M., Ferrara, N. and King, G. L. (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331, 1480-1487. DOI |
34 | Aiello, L. P., Pierce, E. A., Foley, E. D., Takagi, H., Chen, H., Riddle, L., Ferrara, N., King, G. L. and Smith, L. E. (1995) Suppression of retinal neovacscularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. U.S.A. 92, 10457-10461. DOI |
35 | Aird, W. C. (2006) Mechanisms of endothelial cell heterogeneity in health and disease. Circ. Res. 98,159-162. DOI |
36 | Semeraro, F., Morescalchi, F., Duse, S., Parmeggiani, F., Gambicorti, E. and Costagliola, C. (2013) Aflibercept in wet AMD: specific role and optimal use. Drug. Des. Devel. Ther. 7, 711-722. |
37 | Arrieta, O., Zatarain-Barron, Z. L., Cardona, A. F., Carmona, A. and Lopez-Mejia, M. (2017) Ramucirumab in the treatment of non-small cell lung cancer. Expert. Opin. Drug. Saf. 5, 637-644. |
38 | Aziz, M. A., Serya, R. A., Lasheen, D. S., Abdel-Aziz, A. K., Esmat, A., Mansour, A. M., Singab, A. N. and Abouzid, K. A. (2016) Discovery of potent VEGFR-2 inhibitors based on Furopyrimidine and thienopyrimidne scaffolds as cancer targeting agents. Sci. Rep. 6, 24460. DOI |
39 | Baek, Y. Y., Lee, D. K., Kim, J., Kim, J. H., Park, W., Kim, T., Han, S., Jeoung, D., You, J. C., Lee, H., Won, M. H., Ha, K. S., Kwon, Y. G. and Kim, Y. M. (2017) Arg-Ley-Tyr-Glu tetrapeptide inhibits tumor progression by suppressing angiogenesis and vascular permeability via VEGF receptor-2 antagonism. Oncotarget. 14, 11763-11777. |
40 | Pierce, E. A., Avery, R. L., Foley, E. D., Aiello, L. P. and Smith, L. E. (1995) Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc. Natl.Acad. Sci. U.S.A. 92, 905-909. DOI |
41 | Shah, R. S., Soetikno, B. T., Lajko, M. and Fawzi, A. A. (2015) A mouse model for laser-induced choroidal neovascularization. J. Vis. Exp. 106, e53502. |
42 | Shibuya, M. (2006) Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt1): a dual regulator for angiogenesis. Angiogenesis 9, 225-230. DOI |
43 | Shi, F., Wang, Y. C., Zhao, T. Z., Zhang, S., Du, T. Y., Yang, C. B., Li, Y. H. and Sun, X. Q. (2012) Effects of simulated microgravity on human umbilical vein endothelial cell angiogenesis and role of the PI3K-Akt-eNOS signal pathway. PLoS ONE 7, e40365. DOI |
44 | Veloso, C. E., de, Almeida, L. N., Recchia, F. M., Pelayes, D. and Nehemy, M. B. (2014) VEGF gene polymorphism and response to intravitreal ranibizumab in neovascular age-related macular degeneration. Ophthalmic. Res. 51, 1-8. DOI |
45 | Simo, R. and Hernandez, C. (2008) Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia 9, 1574-1580. DOI |
46 | Spaide, R. F., Laud, K., Fine, H. F., Klancnik, J. M., Jr., Meyerle, C. B., Yannuzzi, L. A., Sorenson, J., Slakter, J., Fisher, Y. L. and Coonet, M. J. (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26, 383-390. DOI |
47 | Taimeh, Z., Loughran, J., Birks, E. J. and Bolli, R. (2013) Vascular endothelial growth factor in heart failure. Nat. Rev. Cardiol. 9, 519-530. |
48 | Campochiaro, P. A., Aiello, L. P. and Rosenfeld, P. J. (2016) Anti-vascular endothelial growth factor agents in the treatment of retinal disease: from bench to bedside. Ophthalmology 123, S78-S88. DOI |
49 | Baek, Y. Y., Lee, D. K., So, J. H., Kim, C. H., Jeoung, D., Lee, H., Choe, J., Won, M. H., Ha, K. S., Kwon, Y. G. and Kim, Y. M. (2015) The tetrapeptide Arg-Leu-Tyr-Glu inhibits VEGF-induced angiogenesis. Biochem. Biophys. Res. Commun. 463, 532-537. DOI |
50 | Bee, Y. S., Ma, Y. L., Chen, J., Tsai, P. J., Sheu, S. J., Lin, H. C., Huang, H., Liu, G. S. and Tai, M. H. (2018) Inhibition of experimental choroidal neovascularization by a novel peptide derived from calreticulin anti-angiogenic domain. Int. J. Mol. Sci. 19, 10. DOI |
![]() |